Clinical Trial

Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)

Study acronym: RELIEVE-PAH
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 22, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The objectives of the RELIEVE-PAH study are to obtain first-in-human experience with the study device in patients with severe pulmonary arterial hypertension, including evidence of initial safety, device performance and possible signals of clinical effectiveness.
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-23
notable Enrollment reduced: 20 -> 9 participants 2026-06-23
minor Completion moved earlier: 2031-12-31 -> 2028-05 2026-06-23
Trial Details
NCT Number NCT03838445
Lead Sponsor V-Wave Ltd
Conditions Pulmonary Arterial Hypertension
Enrollment 9 participants
Start Date 2020-02-14
Primary Completion 2026-06-30 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-22